KalVista Pharmaceuticals, Inc. PP&E Disclosure
At April 30, 2025 and 2024, property and equipment consisted of (in thousands):
|
|
2025 |
|
|
2024 |
|
||
Leasehold improvements |
|
$ |
3,091 |
|
|
$ |
2,859 |
|
Laboratory equipment |
|
|
2,660 |
|
|
|
2,409 |
|
Furniture & fixtures |
|
|
571 |
|
|
|
402 |
|
Office equipment |
|
|
413 |
|
|
|
269 |
|
Total property and equipment at cost |
|
|
6,735 |
|
|
|
5,939 |
|
Less: Accumulated depreciation |
|
|
(4,747 |
) |
|
|
(3,712 |
) |
Property and equipment, net |
|
$ |
1,988 |
|
|
$ |
2,227 |
|
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Jul 10, 2025 | Showing above |
| 2024 | Jul 11, 2024 | |
| 2023 | Jul 10, 2023 | |
| 2022 | Jul 7, 2022 | |
| 2021 | Jul 13, 2021 | |
| 2020 | Jul 1, 2020 | |
| 2019 | Jul 16, 2019 | |
| 2018 | Jul 30, 2018 | |
| 2017 | Jul 27, 2017 | |
About PP&E Disclosures
The PP&E disclosure details a company's physical asset base — land, buildings, machinery, and equipment — along with the depreciation methods and useful life assumptions that determine how these costs flow through the income statement. Capitalization policy thresholds reveal management's judgment on the boundary between expense and asset, directly affecting both reported earnings and asset values.
Key signals: changes in estimated useful lives or depreciation methods can materially shift reported earnings without any operational change. Compare capital expenditures against depreciation expense — when capex consistently trails depreciation, the asset base may be aging and underinvested. Watch for large asset impairments or write-downs that signal overvalued carrying amounts. Asset retirement obligations reveal future environmental or decommissioning costs that are often underappreciated. Compare PP&E intensity (PP&E-to-revenue) against industry peers to assess capital efficiency and competitive positioning.